drugset / Trial / NCT03718650
Total Tumor Mapping (TTM) for Resectable Pancreatic Cancer
Phase 0
Withdrawn
H. Lee Moffitt Cancer Center and Research Institute
Varian Medical Systems · collab
NaSingle-groupOpen-labelDiagnostic
Summary
At present there is no validated prognostic tool for patients with resectable pancreatic cancer (RPC) to determine how best to tailor individual therapy. This study is to see if tumor features in blood and imaging prior to surgery correspond with tumor heterogeneity in the specimen after surgery.
Timeline
- Start
- 2021-04-01
- Primary completion
- 2022-04-01
- Completion
- 2023-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pimonidazole | Diagnostic / imaging agent | 500 mg/m2 | Oral |